B. Withopf

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

Stefan Blech, Eva Ludwig-Schwellinger, Eva Ulrike Gräfe-Mody et al. · Drug Metabolism and Disposition · 2010 · 187 citations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

S. Hüttner, Eva U. Graefe-Mody, B. Withopf et al. · The Journal of Clinical Pharmacology · 2008 · 133 citations

Pharmacotherapy, Single Oral Doses, Adverse Drug Reaction +18

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

Eva U. Graefe-Mody, Steven J. Padula, Arne Ring et al. · Current Medical Research and Opinion · 2009 · 57 citations

Binding to dipeptidyl peptidase‐4 determines the disposition of linagliptin (BI 1356) – investigations in DPP‐4 deficient and wildtype rats

Silke Retlich, B. Withopf, Andreas Greischel et al. · Biopharmaceutics & Drug Disposition · 2009 · 46 citations

Molecular Pharmacology, Neuropeptides, Signal Transduction +14

Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

Eva U. Graefe-Mody, Thomas Brand, Arne Ring et al. · International Journal of Clinical Pharmacology and Therapeutics · 2011 · 21 citations